14 February 2008
Schering-Plough Animal Health Corporation Launches New 9-Way Clostridial Vaccine
SCHERING-PLOUGH ANIMAL HEALTH CORPORATION LAUNCHES NEW
9-WAY CLOSTRIDIAL VACCINE
CAVALRY 9, Broadest Spectrum Clostridial Vaccine Currently Available to the U.S. Cattle Industry
KENILWORTH, N.J., [February 2008] – Schering-Plough Animal Health Corporation announces the release of CAVALRY 9, a new low-dose, low-reactive clostridial vaccine for cattle. CAVALRY 9 stimulates an immune response against nine different clostridial diseases, making it the most broad spectrum clostridial vaccine available to U.S. cattle producers.
CAVALRY 9, which is licensed under current USDA Potency and Safety Requirements, contains Clostridium tetani, chauvoei, septicum, sordellii, haemolyticum, novyi type B and perfringens types C and D, which also provide cross protection against type B.
“CAVALRY 9 provides maximum prevention against deadly clostridial diseases in cattle,” said Kevin O’Connell, Ph.D., Schering-Plough Animal Health. “It’s a true low-reactive clostridial vaccine, so producers won’t have to worry about site reactions. CAVALRY 9 also has high efficacy, which means it’s both strong and effective in vaccinating against nine clostridial diseases, including tetanus.”
CAVALRY 9 has a proprietary adjuvant known as VIGOR that, when added to the vaccine, stimulates a heightened immune response without local site reactions that are common with some clostridial vaccines.
Two subcutaneous doses of CAVALRY 9 are required, given three weeks apart. Annual revaccination is with a single dose. Cattle three months of age and older may be vaccinated. Calves vaccinated at three to six months of age should be given a third vaccination.
CAVALRY 9 is now available through veterinarians and animal health suppliers.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough’s vision is to “Earn Trust, Every Day” with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com
# # #
Media Contact: Ken Wurdeman